Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Blood|May 4, 2013
Development of a novel redirected T-cell-based adoptive immunotherapy targeting human telomerase reverse transcriptase for adult T-cell leukemiaYukihiro Miyazaki, Hiroshi Fujiwara, Hiroaki Asai, et al.
Oncology Letters|November 20, 2012
Phase I/II study of docetaxel, cisplatin and S-1 in locally advanced, recurrent and metastatic head and neck squamous cell carcinomaYuichiro Tada, Shin-Ichiro Maruya, Takashi Saotome, et al.
Cancer Immunology Research|April 30, 2014
Gene-modified human α/β-T cells expressing a chimeric CD16-CD3ζ receptor as adoptively transferable effector cells for anticancer monoclonal antibody therapyFumihiro Ochi, Hiroshi Fujiwara, Kazushi Tanimoto, et al.
Plos One|February 27, 2013
Co-introduced functional CCR2 potentiates in vivo anti-lung cancer functionality mediated by T cells double gene-modified to express WT1-specific T-cell receptorHiroaki Asai, Hiroshi Fujiwara, Jun An, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|March 22, 2023
Better Peptides via Chemical Glycosylation: Somatostatin Analogues Having a Human Complex-Type N-Glycan with Improved Drug PropertiesHirofumi Ochiai, Taiji Shimoda, Kazuhiro Fukae, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 26, 2018
[A Case of Microangiopathic Hemolytic Anemia with Bone Marrow Carcinomatosis from Breast Cancer]Akari Murakami, Yoshiaki Kamei, Erina Kusakabe, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 25, 2010
[Efficacy of CHOP+/-Rituximab-like therapy plus radiation therapy for patients with diffuse large B-cell lymphoma stage I]Kyoko Ueda, Masahiro Yokoyama, Hiroaki Asai, et al.
Scientific Reports|August 22, 2023
Prognostic value of post-treatment serum soluble interleukin-2 receptor in newly diagnosed diffuse large B-cell lymphoma patients who achieved complete metabolic response following R-CHOP therapyYuko Shirouchi, Noriko Nishimura, Yuko Mishima, et al.
Journal of Hematology & Oncology|January 8, 2014
Adoptive transfer of genetically engineered WT1-specific cytotoxic T lymphocytes does not induce renal injuryHiroaki Asai, Hiroshi Fujiwara, Sohei Kitazawa, et al.
Cancer Science|February 26, 2018
Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myelomaShinsuke Iida, Masashi Wakabayashi, Kunihiro Tsukasaki, et al.
Pageof 2